How do I book my seasonal vaccination appointment?
You will be sent communication from your preferred contact method advising you how to book. this could be through a booking link or through our designated booking line which is open on Saturdays
What if I am housebound?
The practice will contact you from September to book this for appointments starting in October.
What if I cannot attend my seasonal vaccination appointment?
If you are unable to attend your flu vaccination appointment, please cancel this via the NHS App, via our Online Services, or by telephone at 01752 346634.
What can I expect when I attend my appointment:
Please arrive as close to your appointment time as possible to reduce queues.
Please do not attend with another person unless they are a carer.
Please wear appropriate clothing so that you are ready for your injection.
Please be aware that our practice sites will have limited parking due to the number of patients attending these clinics.
Please note clinic on Saturday 4th October 2025, there is only disabled parking available at Ivybridge Health Centre, please find alternative parking in the town centre.
If your appointment is at the Watermark please ensure you register your parking and follow the signs at the entrance and up the stairs. There is a lift on the ground floor.
Patient eligible for COVID AND FLU are different this year information below
This year it has been decided that a COVID-19 vaccine should be offered to those in the population most vulnerable to serious outcomes from COVID-19 and who are therefore most likely to benefit from vaccination.
This decision is based on expert advice from the Joint Committee on Vaccination and Immunisation (JCVI), which continuously monitor and evaluate emerging scientific evidence on COVID-19 vaccines.
The autumn 2025 vaccination programme will target people who are at the highest risk of serious illness to protect the most vulnerable.
The start date for adult flu vaccinations aligns to COVID-19 vaccinations to support co-administration of flu and COVID-19 wherever possible and provide the best possible protection as we head in to winter. All adult cohorts will, start from 1st October 2025.
In line with JCVI advice, frontline health and social care workers (HSCWs) and staff working in care homes for older adults will not be eligible for COVID-19 vaccination under the national programme for autumn 2025.
Vaccination will be offered in England in autumn 2025 to:
The announced and authorised cohorts eligible for a COVID-19 vaccine in AW 2025/26 are:
Residents in a care home for older adults
Persons aged 6 months and over who are immunosuppressed, as defined in tables 3 and 4 of the COVID-19 chapter of the JCVI Green Book. (in the grid on page 2& 3 eligible group for covid highlighted in bold)
Patients eligible for flu only are
Residents in a care home for older adults
All adults aged 65 years and over
Persons aged 6 months and over who are immunosuppressed, as defined in tables 3 and 4 of the COVID-19 chapter of the JCVI Green Book. (in the grid below)
All adults aged 75 years and over
A guide to the COVID-19 autumn vaccination – GOV.UK
National flu immunisation programme 2025 to 2026 letter – GOV.UK
| CLINICAL RISK GROUPS | |
| Chronic respiratory disease (ie copd & Asthma) | Individuals with a severe lung condition, including those with poorly controlled asthma1 and chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema; bronchiectasis, cystic fibrosis, interstitial lung fibrosis, pneumoconiosis and bronchopulmonary dysplasia (BPD). |
| Chronic heart disease and vascular disease | Congenital heart disease, hypertension with cardiac complications, chronic heart failure, individuals requiring regular medication and/or follow-up for ischaemic heart disease. This includes individuals with atrial fibrillation, peripheral vascular disease or a history of venous thromboembolism |
| Chronic kidney disease | Chronic kidney disease at stage 3, 4 or 5, chronic kidney failure, nephrotic syndrome, kidney transplantation |
| Chronic liver disease | Cirrhosis, biliary atresia, chronic hepatitis. |
| Chronic neurological disease | Stroke, transient ischaemic attack (TIA). Conditions in which respiratory function may be compromised due to neurological or neuromuscular disease (e.g. polio syndrome sufferers). This group also includes individuals with cerebral palsy, severe or profound and multiple learning disabilities (PMLD) including all those on the learning disability register, Down’s syndrome, multiple sclerosis, epilepsy, dementia, Parkinson’s disease, motor neurone disease and related or similar conditions; or hereditary and degenerative disease of the nervous system or muscles; or severe neurological disability. |
| Diabetes mellitus and other endocrine disorders | Any diabetes, including diet-controlled diabetes, current gestational diabetes, and Addison’s disease |
| Immunosuppression | Immunosuppression due to disease or treatment, including patients undergoing chemotherapy leading to immunosuppression, patients undergoing radical radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients, HIV infection at all stages, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID). Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil. Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day for adults. Anyone with a history of haematological malignancy, including leukaemia, lymphoma, and myeloma. Those who require long term immunosuppressive treatment for conditions including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, scleroderma and psoriasis Some immunosuppressed patients may have a suboptimal immunological response to the vaccine (see Immunosuppression and HIV). |
| Asplenia or dysfunction of the spleen | This also includes conditions that may lead to splenic dysfunction, such as homozygous sickle cell disease, thalassemia major and coeliac syndrome |
| Morbid obesity | Adults with a Body Mass Index (BMI) ≥40 kg/m² |
| Severe mental illness | Individuals with schizophrenia or bipolar disorder, or any mental illness that causes severe functional impairment |
| Younger adults in long-stay nursing and residential care settings | Many younger adults in residential care settings will be eligible for vaccination because they fall into one of the clinical risk groups above (for example learning disabilities). Given the likely high risk of exposure in these settings, where a high proportion of the population would be considered eligible, vaccination of the whole resident population is recommended. Younger residents in care homes for the elderly will be at high risk of exposure, and although they may be at lower risk of mortality than older residents should not be excluded from vaccination programmes (see priority 1 above). |
| Pregnancy | All stages (first, second and third trimesters) |